An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)Article Published on 2022-01-112022-10-04 Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 임상, [키워드] Abstract administration Anti-inflammatory approach ARDS blockade challenge chemokine Clinical data clinical trial combination therapy Concentration coronavirus disease-2019 COVID-19 Cytokine storm Cytokines dosage downstream drugs dysregulated immune response Efficacy explained Future Health hepatic injury highest Hyperinflammatory IL-6 IL-6 inhibitor IL-6 pathway IL-6 signaling IMPROVE interleukin-6 Jak-STAT Janus-kinase inhibitor lung damage membrane monotherapy non-specific Pathways pleiotropic pro-inflammatory progression pulmonary damage recent receptor reduce risk sarilumab severe coronavirus disease severe COVID-19 Side effect Signaling therapeutic approaches Tocilizumab Treatment [DOI] 10.1016/j.intimp.2022.108536 PMC 바로가기 [Article Type] Article
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 PatientsCOVID-19 환자의 2 개의 항 바이러스 요법 조합의 결과 비교Comparative Study Published on 2022-01-072022-09-10 Journal: BioMed Research International [Category] 치료제, [키워드] antiviral therapies arrhythmia Arrhythmias Atazanavir Bilirubin both group both groups clinical outcomes Clinical symptoms Combination combination therapies combination therapy Complication COVID-19 COVID-19 patients drug during treatment evaluated form Hospital stay Hydroxychloroquine hyperbilirubinemia Lopinavir Lopinavir/ritonavir no significant difference Other outcome patients patients with moderate Protease inhibitor regimen Ritonavir Side effect significant increase significantly statistically significant therapeutic Treatment treatment regimens two group two groups [DOI] 10.1155/2022/1522426 PMC 바로가기 [Article Type] Comparative Study
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 PatientsComparative Study Published on 2022-01-072022-10-27 Journal: BioMed Research International [Category] COVID-19, [키워드] antiviral therapies arrhythmia Bilirubin both group clinical outcomes Clinical symptoms Combination combination therapy Complication COVID-19 COVID-19 patients drug evaluated form Hospital stay Hydroxychloroquine no significant difference Other outcome patients patients with moderate Protease inhibitor regimen Side effect significant increase significantly statistically significant therapeutic Treatment treatment regimens two group [DOI] 10.1155/2022/1522426 PMC 바로가기 [Article Type] Comparative Study
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 PatientsComparative Study Published on 2022-01-072022-10-27 Journal: BioMed Research International [Category] Coronavirus, COVID-19, SARS, [키워드] antiviral therapies arrhythmia Bilirubin both group clinical outcomes Clinical symptoms Combination combination therapy Complication COVID-19 COVID-19 patients drug evaluated form Hospital stay Hydroxychloroquine no significant difference Other outcome patients patients with moderate Protease inhibitor regimen Side effect significant increase significantly statistically significant therapeutic Treatment treatment regimens two group [DOI] 10.1155/2022/1522426 PMC 바로가기 [Article Type] Comparative Study
Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case ReportCase Reports Published on 2022-01-012023-06-13 Journal: Viral immunology [Category] B형 간염, [키워드] Chronic Hepatitis B Clinical cure combination therapy intermittent therapy. NAs Peg interferon [DOI] 10.1089/vim.2021.0112 [Article Type] Case Reports
Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study코로나바이러스 질환 2019 환자에서 파비피라비르 요법과 결합된 미노사이클린의 평가: 사례 시리즈 연구Article Published on 2022-01-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] SARS, 치료제, [키워드] acute respiratory syndrome adverse event anti-inflammatory activity antibacterial activity Antiviral Chain Reaction changes in chemokine combination therapy Control control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cytokine cytokine and chemokine production Cytokines duration of fever duration of hospitalization Efficacy and safety Endpoint evaluated Favipiravir greater groups hospital Inflammatory cytokines interleukin interleukin-6 interleukin-8 Japan MIN Minocycline monotherapy Negative PCR no difference Patient PCR test polymerase chain polymerase chain reaction reduction reported Retrospective study SARS-CoV-2 severe acute respiratory syndrome Coronavirus Severe case severe cases significantly significantly shorter Support therapy Treatment treatment initiation [DOI] 10.1016/j.jiac.2021.09.016 PMC 바로가기 [Article Type] Article
Implementation of an Emergency Department-Embedded Infusion Center for the Administration of Monoclonal Antibody Therapy in Patients With Early COVID-19 Infection초기 COVID-19 감염 환자의 단일클론항체 치료를 위한 응급실 내장 수액센터 구축Article Published on 2022-01-012022-09-12 Journal: Journal of infusion nursing : the official publica [Category] SARS, 진단, [키워드] administration Care center combination therapy Community coronavirus disease COVID-19 Emergency Emergency use authorization Immunocompromised individual infusion monotherapy offered Outpatient pandemic Patient receive resource risk Safe tested therapy Treatment [DOI] 10.1097/NAN.0000000000000453 PMC 바로가기 [Article Type] Article
Management of Persistent SARS-CoV-2 Infection in Patients with Follicular LymphomaArticle Published on 2022-01-012022-11-16 Journal: Acta haematologica [Category] SARS, 치료기술, [키워드] acute respiratory syndrome Admissions analyzed antibody Antiviral B-cell clinical benefits Clinical characteristics clinical evolution combination therapy Consensus convalescent plasma coronavirus coronavirus disease COVID-19 criteria discharge disease Effect evaluated evidenced follicular Follicular lymphoma hematological Immunocompromised patients Immunoglobulin Immunosuppressed Immunosuppression Infection lymphoma management median outcome Patient patients patients required hospitalization patients treated performed Peripheral blood persistent persistent infection Pneumonia polymerase chain reverse transcriptase SARS-CoV-2 severity Steroids survival rate treated Treatment [DOI] 10.1159/000521121 PMC 바로가기
Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—An Interim Report from a Danish Prospective Cohort StudyCommunication Published on 2021-12-282022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% confidence interval Administered age Antibody Response Antibody test baseline biologic Bloods BNT162b2 vaccine Booster vaccine Cambridge Clinical data collected Combination combination therapy COVID-19 pandemic COVID-19 vaccine cut-off defined detection determine disease Disease activity drug Efficacy Gender Germany Healthcare provider Humoral response IgG IgG level IgG response immune response Immunoglobulin information Interim Mainz median medians Moderna mRNA-1273 vaccine Musculoskeletal National Outpatient Patient patient reported outcome patients treated Pfizer Prospective prospective cohort study psoriatic arthritis receiving report reported response Result rheumatoid arthritis risk RMD SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 vaccination SARS-CoV-2 vaccine significant increase significantly higher significantly lower study population tested the median the SARS-CoV-2 Thermofisher treated Treatment USA vaccination Vaccine was measured was used were used [DOI] 10.3390/vaccines10010035 PMC 바로가기 [Article Type] Communication
Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug DevelopmentPlasmodium spp.및 미생물 : 신약 개발을위한 잠재적 적용Review Published on 2021-12-242022-08-31 Journal: Frontiers in Cellular and Infection Microbiology [Category] MERS, SARS, 신약개발, 치료제, [키워드] active against Against Antimalarial drugs antimicrobial application Artemisinin Bacteria caused chemotherapeutic agent combination therapy COVID-19 develop development disease Diseases drug drugs Ebola virus disease effective Endemic example focus fungi help Infectious diseases Influenza influenza pandemic information kill knowledge malaria malaria parasites mechanism mechanism of action microbe microorganism microorganisms New not achieved parasite patients Plasmodium Potential problem protozoan parasite Region repurposing the WHO Treatment Virus Disease viruses [DOI] 10.3389/fcimb.2021.797509 PMC 바로가기 [Article Type] Review